Table 1. miR-183-96-182 cluster in cancer cell proliferation.
| Member of miR-183-96-182 cluster | Oncogene/Tumor suppressor | Target genes | Tested in human cancer tissue | Cell lines | Cancer types | Results |
|---|---|---|---|---|---|---|
| miR-183-96-182 | Oncogene | FOXO1 | -- | L428 | Lymphoma | Promotes cell proliferation [64]. |
| miR-183-96-182 | Oncogene | FGF9, CPEB1, FOXO1 | ✓ | U251, U87 | Glioma | Promotes cell growth [65]. |
| miR-183-96-182 | Oncogene | RAB21(miR-183) RAB40B(miR-96 and miR-183) TNFSF11(miR-96) |
MCF-7, T47D | Breast cancer | Promotes cell proliferation [3]. | |
| miR-183-96-182 | Oncogene | -- | ✓ | T24, UM-UC-3 | Bladder Cancer | Promotes cell proliferation [154]. |
| miR-183-96-182 | Oncogene | -- | -- | R262, R300 UW402, UW426, D341, D384, D425, D458, D556, D283, DAOY | Medulloblastoma | Promote cell proliferation [155]. |
| miR-96, miR-182 | Oncogene | FOXO1 | ✓ | MCF-7, T47D, MDA-MB-231, MDA-MB-435 | Breast cancer | Promote cell proliferation [49]. |
| miR-96, miR-182 | Oncogene | EFNA5 | ✓ | HepG2, Hep3B, Huh7, SK-Hep1 | Hepatocellular carcinoma | Promote cell proliferation [85]. |
| miR-96, miR-182 | Tumor suppressor | - | -- | A375, SK-MEL-28 | Melanoma | Inhibit cell proliferation [52] |
| miR-183 | Oncogene | PDCD4 | ✓ | Eca109, TE13 and EC109, EC9706 | Esophageal cancer | Promote cell proliferation [76, 81]. |
| miR-183 | Oncogene | PDCD4 | ✓ | SGC-7901 | Gastric cancer* | Promote cell proliferation [78]. |
| miR-183 | Oncogene | NEFL | ✓ | U251 | Glioma | Promote cell proliferation [156]. |
| miR-183 | Oncogene | PDCD4 | ✓ | HepG2, Huh7 | Hepatocellular carcinoma | Promote cell proliferation [79]. |
| miR-183 | Oncogene | PDCD4 | -- | SW1990 | Pancreatic cancer | Promote cell proliferation [80]. |
| miR-183 | Oncogene | SOCS-6 | ✓ | PANC-1 | Pancreatic cancer | Promote cell proliferation [157]. |
| miR-183 | Oncogene | SOCS-6 | ✓ | HepG2, Hep3B | Hepatocellular carcinoma | Promote cell proliferation [158]. |
| miR-183 | Oncogene | PP2A-Cα, PP2A-Cβ, PP2A-B56-γ | ✓ | ACHN, A498 | Renal cancer | Promote cell proliferation [104]. |
| miR-183 | Oncogene | DKK-3, SMAD4 | ✓ | PC-3, DU-145, LNCaP | Prostate cancer | Promote cell proliferation [159]. |
| miR-183 | Tumor suppressor | BMI1 | ✓ | AGS, SGC7901, MKN28, MGC803, HGC27 | Gastric cancer* | Inhibit cell proliferation [103]. |
| miR-96 | Oncogene | FOXO1 | ✓ | HEC-1B | Endometrial cancer. | Promote cell proliferation [70]. |
| miR-96 | Oncogene | FOXO1 | -- | HepG2 | Hepatocellular carcinoma | Promote cell proliferation [160]. |
| miR-96 | Oncogene | FOXO1 | ✓ | T24 | Bladder cancer | Promote cell proliferation [68]. |
| miR-96 | Oncogene | FOXO1 | ✓ | PC3, LNCaP, and LNCaP, DU-145, PC3, 22rv-1, and 22Rv1, LNCaP clone FGC, DU145, PC3 | Prostate cancer** | Promote cell proliferation [63, 66, 67]. |
| miR-96 | Oncogene | FOXO1 | ✓ | SW480, SW620 | Colorectal cancer | Promote cell proliferation [62]. |
| miR-96 | Oncogene | FOXO3 | -- | HepG2 | Hepatocellular carcinoma | Promote cell proliferation [160]. |
| miR-96 | Oncogene | FOXO3 | ✓ | SW480, SW620 | Colorectal cancer | Promote cell proliferation [62]. |
| miR-96 | Oncogene | FOXO3 | ✓ | MCF-7, ZR-75-30, BT549, Bcap37, MDA-MB435, SKBR3, MDA-MB453, T47D | Breast cancer | Promote cell proliferation [69]. |
| miR-96 | Oncogene | FOXO3 | ✓ | A549, SPC-A-1 | Lung cancer*** | Promote cell proliferation [61]. |
| miR-96 | Oncogene | RECK | ✓ | MDA-MB-231, MCF-7, MDA-MB-468, MDA-MB-435, T-74D, MDA-MB-453 | Breast cancer | Promote cell proliferation [83]. |
| miR-96 | Oncogene | RECK | ✓ | A549, SK-MES-1, H1299 | Lung cancer*** | Promote cell proliferation [84]. |
| miR-96 | Oncogene | HBP1 | ✓ | U-87 MG, U-251 MG, U-373 MG, M059J | Glioma | Promote cell proliferation [75]. |
| miR-96 | Oncogene | MTOR | ✓ | LNCaP, 22Rv-1 | Prostate cancer | Promote cell proliferation (Under hypoxia) [23]. |
| miR-96 | Tumor suppressor | KRAS | ✓ | HPDE, BxPC-3, PK-8, and MIA PaCa-2, PANC-1, BxPC-3 | Pancreatic cancer | Inhibit cell proliferation [20, 51]. |
| miR-96 | Tumor suppressor | HERG1 | ✓ | PANC-1, SW1990, CFPAC-1, HPAC, BxPC-3 | Pancreatic cancer | Inhibit cell proliferation [89]. |
| miR-96 | Tumor suppressor | GPC1 | ✓ | Panc-1, AsPC-1, BxPC-3 | Pancreatic cancer | Inhibit cell proliferation [90]. |
| miR-96 | Tumor suppressor | ALK | ✓ | Karpas 299, SUP-M2, SU-DHL-1, SR-786, DEL, SH-SY5Y, H2228 | Lymphoma, Neuroblastoma, and lung *** cancer | Inhibit cell proliferation [88]. |
| miR-96 | Tumor suppressor | ATG7 | ✓ | LNCaP, 22rv-1 | Prostate cancer** | Inhibit cell proliferation (Under hypoxia) [23]. |
| miR-96 | Tumor suppressor | REV1, RAD51 | -- | U2OS, HeLa, HCC1937, MDA-MB-231, HCT116, PEO1, PEO1 C4-2 | Multiple tumors | Sensitize cancer cells to cisplatin and PARP inhibition [36]. |
| miR-182 | Oncogene | PDCD4 | -- | A549, SPC-A-1 and A549 | Lung cancer**** | Promote cell proliferation [55, 56]. |
| miR-182 | Oncogene | PDCD4 | ✓ | OVCAR3, SKOV3, OV2008, HEY, 3AO, A2780, HO8910, C13 | Ovarian cancer | Promote cell proliferation [77]. |
| miR-182 | Oncogene | CHL1 | ✓ | TPC-1, BCPAP | Papillary thyroid carcinoma | Promote cell proliferation [161]. |
| miR-182 | Oncogene | SATB2 | ✓ | DLD-1, HCT116, SW480, SW620, Lovo | Colorectal cancer | Promote cell proliferation [162]. |
| miR-182 | Oncogene | FOXF2 | ✓ | HT29, SW480, SW620, HCT116 | Colorectal cancer | Promote cell proliferation [71]. |
| miR-182 | Oncogene | - | ✓ | HCT116, HT29, SW480 | Colon cancer | Promote cell proliferation [163]. |
| miR-182 | Oncogene | CEBPA | ✓ | -- | Hepatocellular carcinoma | Promote cell proliferation [164]. |
| miR-182 | Oncogene | TP53INP1 | ✓ | HEK293, HepG2 | Hepatocellular carcinoma | Promote cell proliferation [86]. |
| miR-182 | Oncogene | LRRC4 | ✓ | U251, SF126, SF767 | Glioma | Promote cell proliferation [165]. |
| miR-182 | Oncogene | TCEAL7 | -- | HEC-1B, RL95-2, AN3CA | Endometrial carcinoma | Promote cell proliferation [166]. |
| miR-182 | Oncogene | CUL5 | ✓ | Ishikawa H | Endometrial carcinoma | Promote cell proliferation [167]. |
| miR-182 | Oncogene | NDRG1 | ✓ | LNCap, PC-3, DU145, 22Rv1 | Prostate cancer****** | Promote cell proliferation [126]. |
| miR-182 | Oncogene | FOXF2, RECK, MTSS1 | ✓ | LNCaP, PC-3, DU145 | Prostate cancer****** | Promote cell proliferation [72]. |
| miR-182 | Oncogene | PFN1 | ✓ | MDA-MB-231 | Breast cancer | Promote cell proliferation [168]. |
| miR-182 | Oncogene | RECK, Smad4 | ✓ | J82, T24, UM-UC-3 | Bladder cancer | Promote cell proliferation [169]. |
| miR-182 | Oncogene | FOXO3 | -- | A549, H1299, CL 1-0, CL 1-5 | Lung cancer**** | Promote cell proliferation [16]. |
| miR-182 | Tumor suppressor | RAD51 | -- | OCI-AML3, MV4-11 | Acute myelogenous leukemia. | Sensitize cancer cells to sapacitabine [21]. |
| miR-182 | Tumor suppressor | MITF, BCL2, cyclin D2 | -- | M23, SP6.5 | Posterior uveal melanoma | Inhibit cell proliferation [102]. |
| miR-182 | Tumor suppressor | RGS17 | -- | CRL-5803, CRL-5889, H2126 | Lung cancer**** | Inhibit cell proliferation [57]. |
| miR-182 | Tumor suppressor | RASA1 | ✓(highly expressed in tumor) | Failed to get to the data | Lung squamous cell carcinoma | Inhibit cell proliferation [58]. |
| miR-182 | Tumor suppressor | CTTN | -- | A549 | Lung cancer**** | Inhibit cell proliferation [153]. |
| miR-182 | Tumor suppressor | ANUBL1 | ✓ | SGC-7901 | Gastric cancer | Inhibit cell proliferation [170]. |
| miR-182 | Tumor suppressor | CREB1 | ✓ | MGC-803, BGC-823, SGC-7901 | Gastric cancer | Inhibit cell proliferation [53]. |
| miR-182 | Tumor suppressor | FLOT1 | ✓ | 786-O, Caki-1 | Renal cell carcinoma | Inhibit cell proliferation [101]. |
| miR-182 | Tumor suppressor | BCL2, P21(Not biologically validated) | -- | PC3, LNCaP | Prostate cancer****** | Inhibit cell proliferation [25]. |
*
Contradictory findings were marked as the same number of *.
Abbreviations: ALK: Anaplastic lymphoma kinase; ANUBL1: Zinc finger, AN1-type domain 4; ATG7: Autophagy related 7; BCL2: B-cell CLL/lymphoma 2; BMI1: BMI1 proto-oncogene; BRCA1: Breast cancer 1 (BRCA1); CEBPA: CCAAT/enhancer binding protein (C/EBP), alpha; CHL1: Cell adhesion molecule L1-like; CREB1: cAMP-responsive element binding protein 1; CTTN: Cortactin; CUL5: Cullin-5; DAP12: DNAX activating protein 12 kDa; DKK-3: Dickkopf homolog-3; EFNA5: EphrinA5, FOXO: Forkhead box O; FOXF2: Forkhead box F2; FGF9: Fibroblast growth factor 9; GPC1: Glypican 1; HBP1: HMG-box transcription factor 1; HERG1: Human ether-a-go-go-related potassium channel; IDH2: Isocitrate dehydrogenase 2; KRAS: Kirsten rat sarcoma viral oncogene homolog; LRRC4: Leucine rich repeat containing 4; MITF: Microphthalmia-associated transcription factor; MTOR: Mechanistic target of rapamycin; MTSS1: Metastasis suppressor 1; NDRG1: N-myc downstream regulated 1; NDRG1: N-myc downstream regulated gene 1; P21: Cyclin-dependent kinase inhibitor 1A; PDCD4: Programmed cell death 4; PFN1: Profilin 1; PP2A: Protein phosphatase 2A; RASA1: RAS p21 GTPase activating protein 1; RECK: Reversion-inducing-cysteine-rich protein with kazal motifs; RAB: Ras-related gtp-binding protein, alternative splice; RAD51: RAD51 recombinase; REV1: REV1, polymerase; RGS17: Regulator of G-protein signaling 17; SATB2: SATB homeobox 2; SMAD4: SMAD family member 4; TCEAL7: Transcription elongation factor A-like 7; TNFSF11: Tumor necrosis factor (ligand) superfamily, member 11; TP53INP1: Tumor protein p53 inducible nuclear protein 1.